The Healthy Brain and Child Development National Consortium Administrative Core

健康大脑和儿童发展国家联盟行政核心

• 批准号: 10748764
• 负责人: CHRISTINA CHAMBERS
• 金额: $ 6.86万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN DIEGO
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-30 至 2026-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10748764
• 关键词: Address; Administrative Supplement; Alcohols; Anxiety; Behavior; Behavioral; Biological; Biology; Birth; Brain; Cannabis; Caregivers; Child; Child Development; Child Health; Childhood; Cognition; Cognitive; Collection; Communities; Complex; Congenital Abnormality; Data Collection; Detection; Development; Education; Ensure; Epigenetic Process; Ethics; Etiology; Evaluation; Exposure to; Family; Fetal Growth; Fetal Reduction; Fetus; Funding; Future; Generations; Genetic; Goals; Health; Healthcare; Heavy Metals; Helping to End Addiction Long-term; Immune; Individual; Infant Health; Knowledge; Language Delays; Language Development; Link; Logistics; Longitudinal Studies; Low Birth Weight Infant; Maternal Health; Mediating; Memory impairment; Metabolic; National Institute of Drug Abuse; Neonatal Abstinence Syndrome; Opioid; Outcome; Parents; Participant; Pathogenicity; Persons; Placenta; Policies; Predisposition; Pregnancy; Pregnant Women; Premature Birth; Prenatal care; Prevention; Prevention strategy; Process; Proteins; Protocols documentation; Psychopathology; Resources; Risk; Sampling; Signaling Protein; Site; Specimen; Tissue Banks; Tissues; Tobacco; Training; Trauma; Umbilical Cord Blood; Umbilical cord structure; United States; adverse outcome; alcohol consumption during pregnancy; data collection site; emotion regulation; fetal; fetal opioid exposure; fetal substance exposure; in utero; inattention; innovation; interest; longitudinal, prospective study; mRNA Expression; maternal opioid use; neonatal health; neurodevelopment; neuroimaging; nutrition; opioid use; opioid use disorder; polysubstance use; pregnant; prenatal; protocol development; racism; response; sample collection; social; substance use; success; toxicant

PROJECT SUMMARY/ABSTRACT Opioid use during pregnancy is widespread and associated with adverse outcomes for the pregnant individual and the developing child, including reduced fetal growth, premature birth, lower birth weight, congenital defects, increased neonatal healthcare, and heightened risk for later behavioral (e.g., anxiety, inattention), cognitive (e.g., memory deficits, delayed language acquisition), and metabolic problems. Despite opioid use being linked to adverse maternal, fetal, and child outcomes, the mechanisms through which these arise and the potential consequences of prenatal opioid exposure for child health and development (e.g., brain and behavior) remain largely unexplored. This lack of etiologic knowledge has contributed to stagnant treatment, prevention, and mitigation efforts leaving individuals and families susceptible to reverberating adverse outcomes. The HEALthy Brain and Child Development (HBCD) Study is a 25-site longitudinal prospective study of early child development in the US that will assess a broad spectrum of biological (e.g., neuroimaging, genetics, epigenetics), behavioral (e.g., cognition and emotional regulation), experiential (e.g., trauma), social (e.g., racism), and health (e.g., psychopathology) factors among ~7,500 nationally-representative pregnant women and their children from pregnancy to mid-childhood. A major goal of the HBCD Study is to increase understanding of the potential consequences of prenatal substance exposures. It will be enriched for maternal substance use during pregnancy (i.e., ~25% of the sample will be using opioids, cannabis, alcohol, and/or tobacco during pregnancy) and offers a unique opportunity to inform our understanding of how the adverse consequences associated with opioid use during pregnancy arise. Although HBCD will be the largest long-term study of early brain and child development outcomes in the US, the core protocol does not include the collection of delivery biospecimens. This Administrative Supplement in response to the NIDA/ORWH Administrative Supplement Notice of Special Interest: HEAL Initiative: Biospecimen Collection in Pregnancy (NOT-DA-23-005) proposes to leverage the HBCD Study by expanding the biospecimen collection of the Core HBCD Protocol to include delivery specimens (placenta, cord tissue, cord blood). Delivery samples will be collected from a sample of HBCD Study participants across up to 14 HBCD sites (encompassing over 2,000 participants) who have submitted applications in response to this NOSI. This will provide an unprecedented resource generating opportunity for the larger scientific community to comprehensively evaluate pathophysiological mechanisms that mediate the connection between opioid and polysubstance use during pregnancy and adverse neonatal, infant, and/or maternal health outcomes and, in turn, inform innovative preventive strategies.

项目摘要/摘要 怀孕期间的阿片类药物使用普遍存在，并与怀孕个人的不良后果有关 and the developing child, including reduced fetal growth, premature birth, lower birth weight, congenital defects, 新生儿医疗保健增加，并增加了以后行为的风险（例如焦虑，注意力不集中），认知（例如， 记忆缺陷，语言获取延迟）和代谢问题。尽管使用阿片类药物链接到 不利的母亲，胎儿和儿童结果，这些产生的机制和潜力 产前阿片类药物暴露对儿童健康和发育的后果（例如，大脑和行为）仍然存在 在很大程度上没有探索。缺乏病因学知识导致了停滞的治疗，预防和 缓解工作使个人和家庭容易回避不良后果。 The HEALthy Brain and Child Development (HBCD) Study is a 25-site longitudinal prospective study of early child development in the US that will assess a broad spectrum of biological (e.g., neuroimaging, genetics, epigenetics), behavioral (e.g., cognition and emotional regulation), experiential (e.g., trauma), social (e.g., racism), and health (e.g., psychopathology) factors among ~7,500 nationally-representative pregnant women and their children from pregnancy to mid-childhood. A major goal of the HBCD Study is to increase understanding of the potential consequences of prenatal substance exposures. It will be enriched for maternal substance use during pregnancy (i.e., ~25% of the sample will be using opioids, cannabis, alcohol, and/or tobacco during pregnancy) and offers a unique opportunity to inform our understanding of how the adverse consequences associated with opioid use during pregnancy arise. Although HBCD will be the largest long-term study of early brain and child development outcomes in the US, the core protocol does not include the collection of delivery biospecimens.这 Administrative Supplement in response to the NIDA/ORWH Administrative Supplement Notice of Special Interest: HEAL Initiative: Biospecimen Collection in Pregnancy (NOT-DA-23-005) proposes to leverage the HBCD Study by expanding the biospecimen collection of the Core HBCD Protocol to include delivery specimens （胎盘，脐带组织，脐带血）。 Delivery samples will be collected from a sample of HBCD Study participants across up to 14 HBCD sites (encompassing over 2,000 participants) who have submitted applications in response to this NOSI. This will provide an unprecedented resource generating opportunity for the larger 科学界全面评估介导联系的病理生理机制 在怀孕期间的阿片类药物和多物质使用以及不良的新生儿，婴儿和/或孕产妇健康之间 结果又为创新的预防策略提供了信息。